natgillin/translations-raw huggingface dataset:
and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted chiral cyclic boronic ester; said process comprising: 
i R5, uzeti zajedno sa atomima kisika i bora koji se nalaze između, formiraju izborno supstituirani hiralni ciklični ester organoborne kiseline;
an ether solvent that has low miscibility with water and a coordinating co-solvent, provided that the coordinating co-solvent constitutes no more than 20% v/v of the reaction mixture wherein the solubility of water in the ether solvent of (i) or (ii) that has low miscibility with water is less than 5% w/w; and wherein the ether solvent of (i) or (ii) that has low miscibility with water constitutes at least 70% v/v of the reaction mixture; 
etersko otapalo koje ima nisku mješavost sa vodom i koordinacijsko ko-otapalo, uz uvjet da koordinacijsko ko-otapalo čini ne više od 20% vol./vol. reakcijske smjese, pri čemu je otopljivost vode u eterskom otapalu (i) ili (ii) koje ima nisku mješavost sa vodom manja od 5% tež./tež.; i pri čemu etersko otapalo (i) ili (ii) koje ima nisku mješavost sa vodom čini najmanje 70% vol./vol. reakcijske smjese;
A process utilizing at least five moles of at least one starting material for forming a compound of formula (XIV): or a boronic acid anhydride thereof, said process comprising: providing a boron "ate" complex of formula (XV): wherein: 
Postupak koji koristi najmanje pet mola najmanje jednog početnog materijala za formiranje spoja formule (XIV): [image] ili njegovog anhidrida organoborne kiseline, pri čemu navedeni postupak sadrži: osiguravanje kompleksa borata formule (XV):
treating the boronic ester compound of formula (XVI) with a reagent of formula M1-N(G)2, where M1 is an alkali metal and each G individually or together is an amino group protecting group, to form a compound of formula (XVII): 
tretman spoja estera organoborne kiseline formule (XVI) sa reagensom formule M1-N(G)2, gdje je M1 alkalni metal i svako G pojedinačno ili zajedno je zaštitna grupa amino grupe, da bi se formirao spoj formule (XVII):
coupling the compound of formula (XVIII) with a compound of formula (XIX); wherein: is a cleavable amino group protecting moiety; and X is OH or a leaving group; 
spajanje spoja formule (XVIII) sa spojm formule (XIX); [image] u kojem: je zaštitna grupa amino grupe koja se može odvojiti; i X je OH ili odlazeća grupa;
removing the protecting group P1 to form a compound of formula (XXI): or an acid addition salt thereof; 
uklanjanje zaštitne grupe P1 da bi se formirao spoj formule (XXI): [image] ili njegova kisela adicijska sol;
deprotecting the boronic acid moiety to form the compound of formula (XIV) or a boronic acid anhydride thereof. 
deprotekcija grupe organoborne kiseline da bi se formirao spoj formule (XIV) ili njegov anhidrid organoborne kiseline.
The process of claim 1, characterized by at least one of the following features (1)-(3): 
Postupak prema patentnom zahtjevu 49, naznačen najmanje jednom od slijdećih karakteristika (1)-(5):
the coupling step (e) comprises the steps: 
korak spajanja (e) sadrži korake:
the protecting group removing step (f) comprises the steps: 
korak uklanjanja zaštitne grupe (f) sadrži korake:
isolating by crystallization the compound of formula (XXI) as its HCl addition salt; 
izolacije putem kristalizacije spoja formule (XXI) kao njene HCl adicijske soli;
the coupling step (g) comprises the steps: 
korak spajanja (g) sadrži korake:
the boronic acid deprotecting step (h) comprises the steps: 
korak deprotekcije organoborne kiseline (h) sadrži korake:
A process utilizing at least five moles of at least one starting material for forming a compound of formula (XIV): or a boronic acid anhydride thereof, comprising the steps: 
Postupak koji koristi najmanje pet mola najmanje jednog početnog materijala za formiranje spoja formule (XIV): [image] ili njegovog anhidrida organoborne kiseline, koji sadrži korake:
contacting the boron "ate" complex of formula (XV) with a Lewis acid under conditions that afford a boronic ester compound of formula (XVI): said contacting step being conducted in a reaction mixture comprising: 
dovođenja u kontakt kompleksa borata formule (XV) sa Lewis-ovom kiselinom pod uvjetima koji daju spoj ester organoborne kiseline formule (XVI): [image] pri čemu se navedeni korak dovođenja u kontakt izvodi u reakcijskoj smjesi koja sadrži:
a coordinating ether solvent that has low miscibility with water; or 
koordinacijsko etersko otapalo koji ima nisku mješavost sa vodom; ili
wherein the solubility of water in the ether solvent of (i) or (ii) that has low miscibility with water is less than 5% w/w; and wherein the ether solvent of (i) or (ii) that has low miscibility with water constitutes at least 70% v/v of the reaction mixture; 
pri čemu je otopljivost vode u eterskom otapalu (i) ili (ii) koji ima nisku mješavost sa vodom manja od 5% tež./tež.; i pri čemu etersko otapalo (i) ili (ii) koje ima nisku otopljivost sa vodom čini najmanje 70% vol./vol. reakcijske smjese;
treating the boronic ester compound of formula (XVI) with a reagent of formula M1-N(Si(R6)3)2, where M1 is an alkali metal and each R6 independently is selected from the group consisting of alkyl, aralkyl, and aryl, where the aryl or aryl portion of the aralkyl is optionally substituted, to form a compound of formula (XVII): 
tretmana spoja estra organoborne kiseline formule (XVI) sa reagensom formule M1-N(Si(R6)3)2, gdje je M1 alkalni metal i svako R6 nezavisno je izabrano iz grupe koju čine alkil, aralkil i aril, gdje je aril ili aril dio aralkila izborno supstituiran, tako da formira spoj formule (XVII):
removing the (R6)3Si groups to form a compound of formula (XVIII): or an acid addition salt thereof; 
[image] uklanjanja (R6)3Si grupa tako da se formira spoj formule (XVIII):
The coupling step (e') comprises the steps: 
Korak spajanja (e’) sadrži korake:
The boronic acid deprotecting step (f') comprises the steps: 
korak deprotekcije organoborne kiseline (f’) sadrži korake:
providing a biphasic mixture comprising the compound of formula (XXIII), an organic boronic acid acceptor, a lower alkanol, a C5-8 hydrocarbon solvent, and aqueous mineral acid; 
osiguravanje dvofazne smjese koja sadrži spoj formule (XXIII), organski akceptor organoborne kiseline, niži alkanol, C5-8 ugljovodično otapalo i vodenu otopinu mineralne kiseline;
stirring the biphasic mixture to afford the compound of formula (XIV); 
miješanja dvofazne smjese da bi se dobilo spoj formule (XIV);
The process of claim 55, wherein addition of hexane or heptane results in crystallization of a cyclic trimeric boronic acid anhydride of formula (XXIV): 
Postupak prema patentnom zahtjevu 55, naznačen time što dodavanje heksana ili heptana ima za rezultat kristalizaciju cilkličnog tripolimernog anhidrida organoborne kiseline formule (XXIV):
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
The compound according to claim 1, wherein the weekly dose of Compound I administered to the patient is 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg or 200 mg. 
Spoj prema zahtjevu 1, naznačen time, što tjedna doza Spoja I koja se primjenjuje kod bolesnika iznosi 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg ili 200 mg.
A preform for blow-moulding a bag-in-container, comprising: an inner layer (11) and an outer layer (12), wherein said preform forms a two layer container upon blow-moulding, and wherein the obtained inner layer (21) of said container releases from the obtained outer layer (22) upon introduction of a gas at a point of interface between said two layers; characterized in that at least one of said inner and outer layers includes at least one additive allowing both inner and outer layers to reach their respective blow-moulding temperatures substantially simultaneously upon heating them together in a single infrared oven. 
Predsklop za formiranje u kalupu puhanjem posude s vrećicom unutar nje, koja sadrži unutarnji sloj (11) i vanjski sloj (12), pri čemu spomenuti predsklop puhanjem u kalupu oblikuje dvoslojnu posudu, i pri čemu se dobiveni unutarnji sloj (21) spomenute posude odvaja od dobivenog vanjskog sloja (22) uvođenjem plina u točki na spoju spomenuta dva sloja; naznačen time da barem jedan od spomenutog unutarnjeg i vanjskog sloja obuhvaća barem jedan aditiv koji omogućava da oba, unutarnji i vanjski sloj njihovim zajedničkim grijanjem u jednoj infracrvenoj peći, u osnovi istovremeno dostignu svoju odgovarajuću temperaturu formiranja u kalupu puhanjem.
The preform according to claim 1, wherein the at least one additive is selected from the group of energy absorbing additives and colorants. 
Predsklop prema patentnom zahtjevu 1, naznačen time da je barem jedan aditiv izabran iz grupe aditiva koji upijaju energiju i bojila.
The preform according to claim 2, wherein the energy absorbing additive is a member being selected from the group consisting of carbon black, graphite, diamond dust, diazonium salts, sulphonium salts, sulfoxonium salts, and iodonium salts. 
Predsklop prema patentnom zahtjevu 2, naznačen time da je aditiv koji upija energiju komponenta koja je izabrana iz grupe koja se sastoji od čađe, grafita, dijamantnog praha, diazonijum soli, sulfonijum soli, sulfoksonijum soli i jodonijum soli.
The preform according to any of the preceding claims, wherein the at least one point of interface is a vent (3) in the shape of a wedge with the broad side at the level of the opening thereof and getting thinner as it penetrates deeper into the vessel, until the inner and outer layers meet to form an interface. 
Predsklop prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je barem jedna točka spoja otvor (3) u obliku klina sa širom stranom u ravnini s njegovim otvorom i postaje tanji kako se proteže dublje u posudu, dok se unutarnji i vanjski slojevi sastanu formirajući spoj.
A process for producing a bag-in-container comprising the following steps: 
Postupak za proizvodnju posude s vrećicom unutar nje obuhvaća slijedeće korake:
The process according to claim 12, wherein the at least one additive is selected from the group of energy absorbing additives and colorants. 
Postupak prema patentnom zahtjevu 12 naznačen time da je barem jedan aditiv izabran iz grupe aditiva koji upijaju energiju i bojila.
The process according to claim 13, wherein the energy absorbing additive is a member being selected from the group consisting of carbon black, graphite, diamond dust, diazonium salts, sulphonium salts, sulfoxonium salts, and iodonium salts. 
Postupak prema patentnom zahtjevu 13 naznačen time da je aditiv koji upija energiju član koji je izabran iz skupine koja se sastoji od čađe, grafita, dijamantnog praha, diazonijum soli, sulfonijum soli, sulfoksonijum soli i jodonijum soli.
A bag-in-container made by the process comprising: 
Posuda s vrećicom u njoj napravljena postupkom koji obuhvaća:
Use of energy absorbing additives or colorants for the substantially simultaneous heating to the respective blow-moulding temperatures of the inner (11) and outer (12) layers of a preform for blow-moulding a bag- in-container. 
Korištenje aditiva naznačeno time da upijaju energiju ili bojila za u osnovi istovremeno zagrijavanje do odgovarajuće temperature oblikovanja u kalupu puhanjem unutarnjih (11) i vanjskih (12) slojeva predsklopa za oblikovanje u kalupu puhanjem posude sa vrećicom u njoj.
The compound of claim 1, wherein R1 is -NR4OR5. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je -NR4OR5.
The use of a compound according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a disease or disorder in a human or animal that can be treated by inhibiting mitosis. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje bolesti ili poremećaja kod čovjeka ili životinje koje se može liječiti inhibiranjem mitoze.
The use of claim 22, wherein said abnormal cell growth condition is cancer, autoimmune disease, arthritis, graft rejection, inflammatory bowel disease, or proliferation induced after medical procedures. 
Upotreba u skladu s patentnim zahtjevom 22, naznačena time što je navedeno stanje s abnormalnim rastom stanica rak, autoimuna bolest, artritis, odbacivanje presatka, upalna bolest crijeva, ili proliferacija do koje je došlo nakon medicinskih zahvata.
the stream of ethane is subjected to a catalytic oxydehydrogenation producing a gas mixture containing ethylene, unconverted ethane, water and secondary constituents; 
struja etana je podvrgnuta katalitičkoj oksidehidrogenaciji koja daje plinsku mješavinu koja sadrži etilen, nepretvoreni etan, vodu i sekundarne sastojke;
after an optional additional purification step, said dry gas mixture is subjected to an absorption A1 which consists of separating said gas mixture into a fraction enriched with the compounds that are lighter than ethylene containing some of the ethylene (fraction A) and into a fraction F1; 
nakon proizvoljnog dodatnog koraka pročišćavanja, navedena suha plinska mješavina podvrgnuta je apsorpciji A1 koja se sastoji od separacije navedene plinske mješavine u frakciju obogaćenu sa spojevima koji su lakši od etilena koja sadrži nešto etilena (frakcija A) i u frakciju F1;
optionally the stream of products derived from the chlorination reactor, from which the 1,2-dichloroethane has optionally been extracted, is subjected to an absorption A2 which consists of separating said stream into a fraction enriched with ethane F2 which is then conveyed back to fraction F1, and into a fraction enriched with compounds that are lighter than ethane F2'; 
proizvoljno je struja produkata dobivena iz reaktora za kloriranje, iz koje je proizvoljno ekstrahiran 1,2-dikloroetan, podvrgnuta apsorpciji A2 koja se sastoji od separacije navedene struje u frakciju obogaćenu sa etanom F2 koja je zatim prebačena natrag u frakciju F1, te u frakciju obogaćenu sa spojevima koji su lakši od etana F2';
the stream of products derived from the oxychlorination reactor, from which the 1,2-dichloroethane has been extracted, optionally containing an additional stream of ethane previously introduced in one of steps b) to g), is recycled to step a); 
struja produkata dobivena iz oksidacijskog reaktora za kloriranje, iz koje je ekstrahiran 1,2-dikloroetan, proizvoljno sadrži dodatnu struju etana koja je prethodno uvedena u jednom od koraka b) do g), ponovno se koristi u koraku a);
Process according to Claim 1, characterized in that the source of ethane contains at least 98 vol% of ethane. 
Postupak prema zahtjevu 1, naznačen time da izvor etana sadrži barem 98 vol% etana.
Process according to Claim 1, characterized in that fraction A contains at least 70 wt% of the compounds that are lighter than ethylene contained in the dry gas mixture. 
Postupak prema zahtjevu 1, naznačen time da frakcija A sadrži barem 70 tež.% spojeva koji su lakši od etilena koji se nalazi u suhoj plinskoj mješavini.
the stream of products derived from the oxychlorination reactor, from which the 1,2-dichloroethane has been extracted, optionally containing an additional stream of ethane previously introduced in one of steps b) to g), is recycled to step a); and 
struja produkata dobivena iz oksidacijskog reaktora za kloriranje, iz koje je ekstrahiran 1,2-dikloroetan, proizvoljno sadrži dodatnu struju etana koja je prethodno uvedena u jednom od koraka b) do g), ponovno se koristi u koraku a); i
the 1,2-dichloroethane obtained is subjected to a pyrolysis thus producing vinyl chloride; and 
dobiveni 1,2-dikloroetan je podvrgnut pirolizi te se tako dobiva vinil klorid; i
the vinyl chloride is polymerized to produce PVC. 
vinil klorid polimerizira da se dobije PVC.
is selected from the group consisting of single carbon-carbon bond and double carbon-carbon bond; 
[image] [image] je odabran iz skupine koja se sastoji od jednostruke veze ugljik-ugljik i dvostruke veze ugljik-ugljik;
Q is a substituent selected from the group consisting of: 
Q je supstituent izabran iz grupe koju čine:
Each Q1 represents a ring independently selected from the group consisting of: cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, wherein said substituted rings are substituted with 1 to 3 substituents independently selected from the group consisting of: the R10 moieties; provided that when Q1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl then the carbon atoms at the ring junction are not substituted; 
[image] [image] svako Q1 predstavlja prsten nezavisno izabran iz grupe koju čine: cikloalkil, supstituirani cikloalkil, heterocikloalkil, supstituirani heterocikloalkil, aril, supstituirani aril, heteroaril i supstituirani heteroaril, pri čemu su navedeni supstituirani prsteni supstituirani sa 1 do 3 supstituenta nezavisno izabrana iz grupe koju čine: R10 grupe; uz uvjet kada je Q1 jednako aril, heteroaril, supstituirani aril ili supstituirani heteroaril tada atomi ugljika na spoju prstena nisu supstituirani;
is selected from the group consisting of: -CN, -NO2, 
je izabran iz grupe koju čine: -CN, -NO2,
is selected from the group consisting of: H, -CN, 
je izabran iz grupe koju čine: H, -CN,
-O-(substituted alkyl) wherein said substituted alkyl is substituted with 1 to 3 F atoms, 
-O-(supstituirani alkil) pri čemu je navedeni supstituirani alkil supstituiran sa 1 do atoma,
R5A is selected from the group consisting of: halo, -OH, and -O-alkyl; 
A je izabran iz grupe koju čine: halo, -OH i -O-alkil;
is selected from the group consisting of: H, alkyl, and -O-alkyl; 
je izabran iz grupe koju čine: H, alkil i -O-alkil;
is selected from the group consisting of: alkyl, aryl, heteroaryl, and cycloalkyl; 
je izabran iz grupe koju čine: alkil, aril, heteroaril i cikloalkil;
The compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein the compound of formula 1.0 is a compound of formula 1.3, and Q is selected from the group consisting of: 2.6 and 2.7, and 2.7 is selected from the group consisting of: and R3, R4, R6, and R7 are each independently selected from the group consisting of: H and alkyl. 
Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, pri čemu, spoj formule 1.0 je spoj formule 1.3, i Q je izabran iz grupe koju čine: 2.6 i 2.7, i 2.7 je izabran iz grupe koju čine: [image] i [image] i svako R3, R4, R6 i R7 nezavisno su izabrani iz grupe koju čine: H i alkil.
The compound of Claim 31, or a pharmaceutically acceptable salt thereof, wherein Q is 2.6, and R3, R4, R6, and R7 are each H. 
Spoj prema patentnom zahtjevu 31, ili njegova farmaceutski prihvatljiva sol, pri čemu je Q jednako 2.6, i svi R3, R4, R6 i R7 su H.
substituted with one or two alkyl groups; 
[image] supstituiran sa jednom ili dvije alkil grupe;
substituted with one or two methyl groups; 
[image] supstituiran sa jednom ili dvije metil grupe;
substituted with one methyl group; and 
[image] supstituiran sa jednom metil grupom; i
substituted with one or two methyl groups; and 
[image] supstituiran sa jednom ili dvije metil grupe; i
substituted with one methyl group. 
[image] supstituiran sa jednom metil grupom.
The compound of Claim 48, or a pharmaceutically acceptable salt thereof, wherein Q is 2.6. 
Spoj prema patentnom zahtjevu 48, ili njegova farmaceutski prihvatljiva sol, pri čemu je Q jednako 2.6.
The compound of Claim 48, or a pharmaceutically acceptable salt thereof, wherein Q is 2.7B. 
Spoj prema patentnom zahtjevu 48, ili njegova farmaceutski prihvatljiva sol, pri čemu je Q jednako 2.7B.
The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is 
Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, pri čemu je Q jednako [image]
The compound of claim 1, selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1 izabran iz grupe koju čine:
for the manufacture of a medicament for treating cancer, wherein said medicament is in a form for administration with at least one chemotherapeutic agent; or 
za proizvodnju lijeka za liječenje kancera, pri čemu je navedeni lijek u obliku za primjenu sa najmanje jednim kemoterapeutskim sredstvom; ili
for the manufacture of a medicament for treating cancer, said medicament is in a form for administration with at least one chemotherapeutic agent, and radiation therapy. 
za proizvodnju lijeka za liječenje kancera, pri čemu je navedeni lijek u obliku za primjenu sa najmanje jednim kemoterapeutskim sredstvom, i radijacijskom terapijom.
for the manufacture of a medicament for treating cancer wherein said cancer is selected from the group consisting of: lung cancer, pancreatic cancer, colon cancer, myeloid leukemias, thyroid cancer, myelodysplastic syndrome, bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, prostate cancer, head and neck cancers, ovarian cancer, brain cancers, cancers of mesenchymal origin, sarcomas, tetracarcinomas, nuroblastomas, kidney carcinomas, hepatomas, non-Hodgkin's lymphoma, multiple myeloma, and anaplastic thyroid carcinoma; 
za proizvodnju lijeka za liječenje kancera, pri čemu je navedeni kancer izabran iz grupe koju čine: kancer pluća, kancer pankreasa, kancer debelog crijeva, mijeloidne leukemije, kancer štitnjače, mijelodisplastični sindrom, karcinom bešike, epidermalni karcinom, melanom, kancer dojke, kancer prostate, kanceri glave i vrata, kancer jajnika, kancer mozga, kanceri mezenhimalnog porijekla, sarkomi, tetrakarcinomi, nuroblastomi, karcinomi bubrega, hepatomi, ne-Hodgkin-ov limfom, multipli mijelom i anaplastični tiroidni karcinom;
for the manufacture of a medicament for treating cancer wherein said medicament is in a form for administration in combination with at least one chemotherapeutic agent, and wherein said cancer is selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer. 
za proizvodnju lijeka za liječenje kancera, pri čemu je navedeni lijek u obliku za primjenu u kombinaciji sa najmanje jednim kemoterapeutskim sredstvom, i pri čemu je navedeni kancer izabran iz grupe koju čine: melanom, kancer pankreasa, kancer štitnjače, kolorektalni kancer, kancer pluća, kancer dojke i kancer jajnika.
for the manufacture of a medicament for treating melanoma; 
za proizvodnju lijeka za liječenje melanoma;
for the manufacture of a medicament for treating melanoma, wherein said medicament is in a form for administration in combination with at least one chemotherapeutic agent; 
za proizvodnju lijeka za liječenje melanoma, pri čemu je navedeni lijek u obliku za primjenu u kombinaciji sa najmanje jednim hemoterapeutskim sredstvom;
for the manufacture of a medicament for treating pancreatic cancer; 
za proizvodnju lijeka za liječenje kancera pankreasa;
for the manufacture of a medicament for treating pancreatic cancer, wherein said medicament is in a form for administration with at least one chemotherapeutic agent; 
za proizvodnju lijeka za liječenje kancera pankreasa, pri čemu je navedeni lijek u obliku za primjenu sa najmanje jednim hemoterapeutskim sredstvom;
for the manufacture of a medicament for treating thyroid cancer; 
za proizvodnju lijeka za liječenje kancera štitnjače;